Cantor Fitzgerald analyst Carter Gould has begun coverage on AbbVie Inc. (ABBV, Financial), assigning an Overweight rating with a price target of $210. Gould highlights AbbVie's robust performance in growth and resilience, coupled with a distinct sales growth strategy.
According to the analysis, AbbVie exhibits strong visibility on crucial near-term drivers with minimal clinical risk. The company has successfully moved past the challenges associated with Humira's loss of exclusivity, providing a clearer path forward. Notably, there are no significant binary data events expected through 2025, offering a stable outlook for investors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for AbbVie Inc (ABBV, Financial) is $213.68 with a high estimate of $251.00 and a low estimate of $173.00. The average target implies an upside of 25.58% from the current price of $170.16. More detailed estimate data can be found on the AbbVie Inc (ABBV) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, AbbVie Inc's (ABBV, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AbbVie Inc (ABBV, Financial) in one year is $167.84, suggesting a downside of 1.36% from the current price of $170.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AbbVie Inc (ABBV) Summary page.
